Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18059195 | 0.82 | HRH3 (0.69) | HRH3FAAHALDH1A1MAPTNAAA | |
| SCHEMBL21795201 | 0.81 | HRH3 (0.61) | HRH3FAAHALDH1A1RECQLGAA | |
| SCHEMBL12346213 | 0.81 | FAAH (0.73) | FAAHRECQLGAATSHRMCL1 | |
| SCHEMBL22828585 | 0.80 | HRH3 (0.53) | HRH3ALDH1A1RECQLTSHRHPGD | |
| SCHEMBL23869714 | 0.80 | HRH3 (0.53) | HRH3ALDH1A1RECQLTSHRMCL1 | |
| SCHEMBL10445885 | 0.80 | HRH3 (0.77) | HRH3FAAHALDH1A1 | |
| SCHEMBL23133369 | 0.79 | FAAH (0.46) | HRH3FAAHALDH1A1RECQLGAA | |
| SCHEMBL7737049 | 0.78 | HRH3 (0.81) | HRH3FAAHALDH1A1TSHR | |
| SCHEMBL3760754 | 0.78 | HRH3 (0.81) | HRH3FAAHALDH1A1TSHR | |
| SCHEMBL2907984 | 0.78 | HRH3 (0.81) | HRH3FAAHALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | FCER2, SQLE, TTL | HRH3 770/4885FAAH 2362/4885ALDH1A1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.